Recognising that RCTs provide the best evidence in comparisons of treatment, rehabilitative or preventive regimens, the Cochrane Collaboration has established an international network of centres that systematically attempt to identify, document, and make available for reference all published and unpublished RCTs. 4 The impact of this global initiative in improving the outcome of clinical practice will be dependent on the extent to which clinicians change their practice in the light of available medical evidence. The formation in the UK of the Cochrane Collaborative Review Group on EVective Professional Practice, which focuses on reviews of eVectiveness of diVerent approaches to implementation of evidence-based clinical guidelines, 5 and the NHS centre for the dissemination of reviews are two initiatives that seek to promote the adoption of evidencebased clinical guidelines and appropriate changes in clinical practice.
One of the authors of this report (HC) is registered with the Cochrane Collaboration to coordinate hand searching of the Archives of Disease in Childhood to identify all published RCTs. This review reports on a descriptive study based on hand searching 15 years of the Archives of Disease in Childhood (excluding the Fetal and Neonatal edition) to identify all RCTs. The data on RCT citations have been made available to the Cochrane Collaboration as part of the international eVort to identify RCTs within paediatric practice. In addition to this information we used a structured questionnaire to collect additional specific descriptive data from each of the RCTs identified. This review describes the 249 RCTs published in Archives of Disease in Childhood from 1982-96, and presents some conclusions and recommendations based on our review.
Methods

IDENTIFICATION OF RCTs AND INCLUSION
CRITERIA
We systematically hand searched all regular issues of Archives of Disease in Childhood published from January 1982 to December 1996. We did not include the Fetal and Neonatal editions throughout this period but anticipate hand searching these in the next phase of the exercise. In each volume every article was read, including all annotations, review articles, and letters to the editor. A standard form obtained from one of the Cochrane Collaborative review groups (on peripheral vascular diseases) was completed for each study that was an RCT (randomisation by computer, pharmacy codes, random numbers, coin crossing, sealed envelope, or by an unspecified random method); a quasi-RCT (randomisation by date of birth, days of the week, case record, or alternation); or a controlled clinical trial in which there was no mention of the word "random" but where the trial had one of the following features-controlled, double blind, placebo controlled, or crossover design. A separate note was made of all reviews or meta-analyses of RCTs published.
DESCRIPTIVE DATA COLLECTED ON EACH RCT
In addition to these data, which were gathered for the purposes of the Cochrane controlled trials register, a number of additional pieces of data were recorded (table 1) in a systematic manner from each RCT or quasi-RCT in an attempt to describe these in detail. These data included the country or region in which the trial was carried out, the primary setting for the trial (hospital inpatient, hospital outpatient, or community setting) and the subspecialty area of paediatric practice involved. We also gathered data on characteristics of the study design including method of allocation to treatment groups, unit of allocation, trial structure (parallel group, crossover, or factorial design), number of children recruited, nature of the primary intervention, and outcome of the RCT. Finally we recorded the funding source.
QUALITY ASSESSMENT
Three key parameters of the quality of the RCT design were also assessed against published standards. 6 7 Thus all trials were scored according to the following three factors.
How subjects were allocated to the diVerent treatments (control of selection bias on entry)
This considered whether those enroling study participants could know which treatment was next to be assigned. + RCTs that used blinding of randomisation assured by telephone communication or indistinguishable drug treatments randomly precoded by a pharmacy were given a score of 3. + RCTs using sealed envelopes and therefore creating a small chance of the next treatment being discovered by those enroling participants were given a score of 2. + Trials in which there was no attempt at blinding of the treatment allocation-for example, by use of patient record numbers, birth dates, dates of admission, or alternate allocation were given a score of 1.
Extent to which the primary analysis was based on all participants allocated to receive one or other of the alternative treatments (control of selection bias after entry) + Trials in which the primary analysis was based on all cases entered were given a score of 3. + Trials in which withdrawals were judged to be too few to engender any major bias were given a score of 2. + Others were given a score of 1. After checks were made for range and logic errors and missing data (original RCT reports were reviewed where necessary to capture required data), frequency tables were produced. To look at trends over time RCTs were grouped into three five-year bands according to their publication date. Because of small numbers in individual areas, RCTs were also Quality of random allocation (control of selection bias at entry)
Extent to which primary analysis included every person entered into the randomised cohorts (control of selection bias after entry) Extent to which those assessing outcome were kept unaware of the group assignment of the individuals examined (control of bias in assessing outcome) grouped by specialty area of paediatrics for some analyses. These areas were general paediatrics (including infectious diseases, allergies, and dermatology), respiratory, neonatal, and other specialties (including cardiology, endocrinology, gastroenterology, haematology, oncology, nephrology, neurology, and surgery and anaesthesia). Respiratory and neonatal paediatrics were the specialty areas with the largest representation among published RCTs. (228) or quasi-RCTs (21) Tables 3 and 4 illustrate the type of trial design (crossover, factorial, or parallel groups), the principal setting of the trial (inpatient, outpatient, or community based) and nature of intervention (pharmaceutical only, pharmaceutical plus placebo control, nonpharmaceutical) by paediatric specialty grouping. These show the small number of factorial design RCTs and the scarcity of community based RCTs published in areas outside general paediatrics. Respiratory medicine is the only specialty area in which most trials of pharmaceutical interventions were placebo controlled (47/73 (64%) in respiratory paediatrics v 37/103 (36%) for RCTs in other specialty areas). Pharmaceutical companies gave funding support to 47/84 (56%) of all placebo controlled RCTs compared to 61/165 (37%) of all other RCTs. Table 5 shows the number of RCTs reported by geographic area. This shows that both the absolute number and proportion of RCTs published in the Archives of Disease in Childhood from European and Asian centres have increased whereas the numbers from North America, Australia, and Africa have decreased over the 15 year period.
Results
A total of 249 original reports of RCTs
Many of the published reports gave insuYcient details to be able to assess key quality features of trial design. Reporting of details for blinding of outcome assessment (published in 94% of reports) and completeness of data in the primary analysis (in 100% of reports) were excellent, but fewer than half (43%) of the RCTs gave details about randomisation procedures suYcient to enable assessment, and this did not improve over the 15 year period. The failure to give adequate information about randomisation procedures was more noticeable among single centre (125/204 (61%)) compared to multicentre (17/45 (38%)) RCTs. Table 6 shows the assessment of quality criteria in each of three successive five year periods. Of studies that gave suYcient information for assessment, an increasing number were scored in the highest category for attention to proper randomisation procedures, but a decreasing number scored in the highest category for completeness of data in the primary analysis over the 15 year period. A higher proportion of RCTs in respiratory medicine failed to give adequate information on randomisation 60/82 (73%) compared to trials in other areas 82/167 (49%) (table 7).
The consent rate was not reported in 112 trials (45%). In studies in which consent rates were reported, the rate was reported to be 100% in a very high proportion (111/137 (81%)) of studies. Consent rates varied with the study setting: of those that reported the rate, the consent rate was 100% in 51/57 (90%) inpatient studies, 51/65 (78%) outpatient studies, and 9/15 (60%) community studies. Consent also varied by specialty area with 100% consent rates reported (in studies that reported consent rates) by 23/34 (68%) general paediatric trials, 29/36 (81%) respiratory trials, 27/28 (96%) neonatal trials, and 32/39 (82%) in other speciality areas.
Forty five trials (18%) were multicentre RCTs, 13 published in 1982-86 (16% of all RCTs in this period), 13 (18%) in 1987-91, and 19 (20%) in 1992-96. Thirty (67%) of these trials were UK based compared to 57% of single centre RCTs. The proportion of RCTs that were multicentre in the various paediatric specialty areas was as follows: general paediatrics 23%, respiratory paediatrics 15%, neonatal paediatrics 11%, and other specialty areas 14%. The sources of funding for these RCTs were pharmaceutical companies in 23 (51%), research councils in 13 (29%), government sources in 5 (11%), charitable agencies in 7 (16%), and other specified source or source not given in 2 (4%). This pattern of funding was not significantly diVerent from that for single centre RCTs. Where there was suYcient information to assess the quality of trial design according to the quality criteria noted above, the proportion of RCTs that scored the highest quality ratings in the following areas were: quality of random allocation, multicentre 46%, single centre 51%; blinding of outcome assessment, multicentre 44%, single centre 41%; and completeness of data in the primary analysis, multicentre 27%, single centre 45%. Table 8 shows the sources of funding support for the published trials by individual specialty areas.
Discussion
RCTs from a broad range of paediatric practice were published. RCTs in general paediatrics (69/249 (28%)) and respiratory paediatrics *Proportion of studies that gave suYcient information for this to be assessed. †Highest quality category comprised those with a score of 3. General paediatrics  30  13  8  4  3  69  Respiratory medicine 38  22  12  6  4  82  Neonatology  12  9  5  2  1  35  Endocrinology  15  3  4  1  0  23  Gastroenterology  4  1  1  -1  12  Neurology  1  6  1  -2  8  Haematology/  oncology  2  3  ---7  Cardiology  3  1  ---5  Nephrology  3  2  3  --5  Surgery/  anaesthesiology  -----3  Total  108  60  34  13  11  249 Most RCTs reported in the Archives of Disease in Childhood recruited a very small number of children. Approximately half of all RCTs recruited fewer than 40 children in total (thus fewer than 20 to each treatment group). There are a number of identified benefits from small clinical trials, 11 nevertheless it is equally clear that these have inadequate power to detect small or moderate treatment eVects and result in a significant chance of reporting false negative results. 11 12 Only 18% of RCTs had multicentre collaboration. It may be that larger and more powerful multicentre trials tend to be reported in other paediatric journals, nevertheless it appears that there is a need to encourage multicentre collaboration to address important therapeutic questions in paediatric practice. Some national mechanism within the UK should be considered to foster this, perhaps under the auspices of the new Royal College of Paediatrics and Child Health. There were very few RCTs with a factorial design. This is likely to be caused in part by the small sample sizes in the reported RCTs but may also reflect an unfamiliarity with this eYcient RCT design, which can evaluate more than one intervention and interactions among interventions within a single trial design.
There were relatively few RCTs (31; 12% of all RCTs) published that were done in the community setting. The reasons for this are not clear. Community paediatricians may submit RCTs to more specialist journals, they may have diYculty raising funding for RCTs, or they may be less active in research into treatment interventions in paediatric practice than are other paediatricians in more well established paediatric specialties. The great majority of published RCTs that took place in the community setting were in the area of general paediatrics. This may reflect the greater ease of recruiting patients in other areas of paediatric practice from outpatient specialty clinics or inpatient settings.
Only 84/176 (48%) RCTs involving pharmaceutical interventions were placebo controlled. More than half of these were in respiratory paediatrics and 47/84 (56%) were funded by pharmaceutical companies. This may reflect the fact that it is diYcult to obtain adequate placebos without the collaboration of pharmaceutical companies. Publication of details of other sources of assistance in preparing suitable placebos might be helpful.
There is a need for better reporting of fundamental details of RCT design. The proportion of RCTs reporting details of key quality parameters has not increased over the 15 year period. This is disappointing given the recent widespread dissemination of information on RCT design and quality. This information is necessary to allow readers to interpret RCT findings and to assess their relevance to their own clinical practice. There are accepted quality criteria published for the key parameters detailed in this review: randomisation procedures, control of blinding of outcome assessment, and completeness of data entered into the primary analysis. 6 7 The Archives of Disease in Childhood should consider requiring these details to be given as part of its editorial review procedures [see Introduction].
We believe that consent rates should be explicitly stated (currently about half of all reports do not state this). We are concerned that consent rates appear to be extremely high in the great majority of RCTs. The fact that 90% of all RCTs in inpatient settings and 96% of all RCTs in neonatal paediatrics reported 100% consent may raise the question as to whether such consent is truly informed. It seems likely that if parents were fully informed of their options and freely able to choose not to take part at least some would choose not to, for a variety of reasons. It is possible that investigators who published RCTs with 100% consent rates were more likely to include a note of the consent rate in the publication, believing this to be an indicator of the quality of the RCT. An alternative, although perhaps less likely, explanation of these findings is that practices varied among settings with respect to application of inclusion/exclusion criteria. It is possible that failure to give consent was considered as an exclusion criterion (rather than being recorded as eligible for study but refusing to give consent), particularly in RCTs carried out in inpatient settings and in RCTs involving neonates. We recommend that this should not be done but that consent rate should be reported separately and, before acceptance of the article, authors should be invited to comment on the consent rate if it is reported to be 100%.
Thirty per cent of RCTs reported negative results. This is somewhat reassuring as reviews of RCTs in some other journals have reported very high proportions of RCTs with positive results suggesting publication bias. This can be caused by factors related to the journal in question or the authors, and has been discussed recently. 13 The capture of RCTs by MEDLINE search strategies is improving, principally because of improved indexing of articles with respect to RCTs. 3 8 The sensitivity of MEDLINE searching for RCTs published in Archives of Disease in Childhood was considerably higher than values reported with other journals in 1994. 8 However, this is still at best only about 90% of RCTs, and in some paediatric specialty areas considerably less than this; therefore, there is still scope for improved indexing of original articles published in Archives of Diseases in Childhood so that RCTs are more completely identified.
We thank Dr K Cheng of the Cochrane Cystic Fibrosis Group, Alder Hey Children's Hospital, Liverpool for her assistance and advice in the handsearching exercise, and Professor M Preece, Institute of Child Health, London for forwarding to us a note of all RCTs published in the Archives of Disease in Childhood over the period 1984-92 which he identified by handsearching.
Addendum
Citation information from this handsearching study have been forwarded to the Cochrane centre in Baltimore, details of the RCTs can be obtained from them. Anyone interested in contributing to further handsearching of Archives of Disease in Childhood will be warmly welcomed and should contact Dr H Campbell. Describe mechanism (eg, capsules, tablets); similarity of treatment characteristics (eg, appearance, taste); allocation schedule control (location of code during trial and when broken); and evidence for successful blinding among participants, person doing intervention, outcome assessors, and data analysts Results Participant flow and follow up Provide a trial profile (fig) summarising participant flow, numbers and timing of randomisation assignment, interventions, and measurements for each randomised group Analysis State estimated eVect intervention on primary and secondary outcome measures, including a point estimate and measure of precision (confidence interval) State results in absolute numbers when feasible (eg, 10/20, not 50%). Present summary data and appropriate descriptive and inferential statistics in suYcient detail to permit alternative analyses and replication Describe prognostic variables by treatment group and any attempt to adjust for them Describe protocol deviations from the study as planned, together with the reasons Comment State specific interpretation of study findings, including sources of bias and imprecision (eternal validity) and discussion of external validity, including appropriate quantitative measures when possible State general interpretation of the data in light of the totality of the available evidence
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